Didymin can improve the hepatic fibrosis mainly by inhibition of ERK/MAPK and PI3K/Akt pathways through increasing Raf kinase inhibitor protein (RKIP) expression in HSCs100. This evidence concerns the gene PEBP1 and fibrosis.